WO2005062893A2
|
|
Anti-cd52 antibody treatment for diabetes
|
US2005187193A1
|
|
Alpha-substituted beta-aminoethyl phosphonate derivatives
|
WO2004092339A2
|
|
Modulation of muc1 mediated signal transduction
|
AU2003277416A1
|
|
Clofarabine and platinum chemotherapy combination
|
AU2003301245A8
|
|
Clofarabine and camptothecin chemotherapy combination
|
AU2003287081A8
|
|
Clofarabine and taxane chemotherapy combination
|
AU2003228990A1
|
|
Hydroxyphosphonates and phosphonophosphates as apolipoprotein e modulators
|
EP1506208A2
|
|
1,1- and 1,2-bisphosphonates as apolipoprotein e modulators
|
US7208481B2
|
|
Aminodiphosphonate apolipoprotein E modulators
|
EP1485106A2
|
|
Phosphonate-phosphate and diphosphonate apolipoprotein e modulators
|
EP1482953A1
|
|
Alpha-substituted heteroarylalkyl phosphonate derivattives
|
NZ534794A
|
|
Alpha-substituted arylalkyl phosphonate derivatives for lowering plasma levels of apo (a), lipoproteins and of total cholesterol
|
WO03032909A2
|
|
Methods of treating skin with diphosphonate derivatives
|
US6680382B2
|
|
Process for preparing purine nucleosides
|
US6664401B2
|
|
Process for preparing isocoumarins
|
US6900239B2
|
|
Tumor chemopotentiation using isocoumarin derivatives
|
AU2001294792B2
|
|
Alpha-substituted beta-aminoethyl phosphonates
|